#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dermatitis Cystic fibrosis gastrointestinal disease Pulmonary fibrosis Medulloblastoma recurrent Fragile X syndrome Gastroenteropancreatic neuroendocrine tumour disease Hepatic cirrhosis Gaucher's disease type I Colon cancer Cholestatic pruritus Nodal marginal zone B-cell lymphoma White matter lesion Angiosarcoma metastatic Sexually transmitted disease Pyruvate dehydrogenase complex deficiency More trials…

    Learn about Rare Diseases

    Idiopathic pulmonary fibrosis – Diagnostics Alternating hemiplegia of childhood – Life with Disease Pemphigus Splenic marginal zone lymphoma – Trials in Disease Biotinidase deficiency Burkitt’s lymphoma – Life with Disease Ewing’s sarcoma recurrent – Life with Disease Loeys-Dietz syndrome – Treatment Lennox-Gastaut syndrome – Diagnostics Cystic fibrosis lung – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Azacitidine DCC-3084 Mercaptopurine Hydroxychloroquine Sulfate Azelastine Hydrochloride Allo-647 Azd3470 Lib-01 Monohydrate Eptacog Beta (Activated) Betamethasone Valerate NORGESTIMATE L-SERINE Epirubicin Hydrochloride Buclizine Hydrochloride Topiramate Nofazinlimab Eclitasertib Propofol Immunostimulants RNMB1 More therapies…

    Learn about Your Condition

    Alcohol use disorder Acute leukaemia Dupuytren's contracture Anal cancer stage II Cystic fibrosis Pneumonia Breast cancer male Tuberous sclerosis complex Partial lipodystrophy Primary biliary cholangitis Mesothelioma Erythema migrans Colon cancer metastatic Endometrial cancer Tympanic membrane perforation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Universitaire Rouen

Centre Hospitalier Universitaire Rouen

1 Rue De Germont, Bp 96031, Rouen, 76031, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Olaparib
    Austria France Germany Poland Romania Spain

  • Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cutaneous T-cell lymphoma
    • Cutaneous T-cell lymphoma recurrent
    Investigated Drugs:
    • Lacutamab
    Belgium France Germany Italy Poland Spain

  • Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Czechia Denmark France Germany Ireland Italy +2

  • Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

    Not recruiting

    2 1
    Investigated Drugs:
    • Ianalumab
    Austria Belgium France Germany Hungary Spain

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Austria Denmark France Italy Spain Sweden

  • Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Belgium Bulgaria Czechia Denmark France +6

  • Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Padeliporfin
    Austria France Germany Italy Spain

  • Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Belgium Bulgaria Czechia Denmark France Germany +9

  • Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Selpercatinib
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Effectiveness of Baricitinib for Patients with Refractory Non-Infectious Uveitis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Baricitinib
    • Fluorescein Sodium
    • Prednisone
    France
Previous Page
1 … 38 39 40 41 42 … 48
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!